CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

“As we head into the final quarter of the year, our mission remains centered on delivering meaningful developments for patients battling brain and CNS cancers. We continue to build momentum with our lead product candidate TPI 287 and work towards important, catalytic milestones. With Phase 1 data indicating potential blood-brain barrier penetration and tumor responses, we are aggressively advancing towards our Phase 2 study in GBM. We believe TPI 287 has the potential to be a meaningful new option for patients with brain tumors. Leveraging our established clinical data and team of experts, we are positioned to drive this program forward while creating value for our stakeholders. In the months ahead, we aim to concentrate on initiating the next chapter of TPI 287’s development and delivering on our commitment to execute with urgency and precision,” commented John Climaco, CEO of CNS Pharmaceuticals (CNSP).